Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Cytarabine + daunorubicin) by CSPC Pharmaceutical Group for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
(Cytarabine + daunorubicin) is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Acute Myelocytic Leukemia...